NPM1 and chronic myelomonocytic leukemia: Contributing to 3% of NPM1 mutant cases, CMML with NPM1 mutation shows chemosensitivity to anthracyclines and cytarabine (7 + 3 induction chemotherapy), and hypomethylating drugs have promising effects in maintaining remission [55,57].